Haematologists in the UK have demonstrated impaired antibody response to COVID-19 vaccination in patients with chronic myeloid neoplasms. Oxford University researchers measured anti-SARS-Cov2 IgG spike (S) antibody levels in 60 patients, more than two weeks following a single dose of either Pfizer (BNT162b2) or the AstraZeneca-Oxford (AZD1222) vaccines. The study published in the British Journal ...
Patients with chronic myeloid cancers may not be protected by COVID-19 vaccines
By Mardi Chapman
17 Jun 2021